Clinical Trials Logo
  1. Home
  2. Carcinoma, Basal Cell
  3. NCT01204073

A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Carcinoma, Basal Cell Clinical Trial

Official title:
A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Clinical Trial Summary

This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer effective or does not offer curative or life-prolonging potential. Following completion of the dose escalation study, patients will be enrolled as part of 2 expansion cohorts.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01204073
Study type Interventional
Source Millennium Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1
Start date October 2010
Completion date January 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT00875381 - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin N/A
Recruiting NCT04362722 - Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients Phase 2
Completed NCT00218829 - DMSO-PDT of BCC - A 6 Year Follow up N/A
Completed NCT02674009 - Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT02956889 - To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma Phase 2
Completed NCT02029352 - Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Phase 2/Phase 3
Completed NCT03569345 - Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate Phase 1/Phase 2
Recruiting NCT05463757 - Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Completed NCT00189280 - Aldara for the Treatment of Large and/or Multiple sBCC Phase 3
Completed NCT03541252 - Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study Phase 1/Phase 2
Recruiting NCT05133427 - HIFU for Treatment of Non-nodular and Recurrent BCC N/A
Active, not recruiting NCT02367547 - Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL Phase 1/Phase 2
Completed NCT00007631 - Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Phase 3
Active, not recruiting NCT05138328 - Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance N/A
Completed NCT03132636 - PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy Phase 2
Completed NCT00847912 - CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Phase 4
Enrolling by invitation NCT02666833 - Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers N/A
Completed NCT01482104 - New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) N/A
Completed NCT01455363 - Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma N/A